Applied Therapeutics CEO Shendelman Steps Down

Dow Jones

20 Dec 2024

By Paul Ziobro

Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO.

Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position.

"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities," said Teena Lerner, Applied Therapeutics' lead independent director.

Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas.

Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

December 20, 2024 07:35 ET (12:35 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2492417688"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492417688\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492417688?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492417688","market":"nz","top_or_hot":-1,"title":"Applied Therapeutics CEO Shendelman Steps Down","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<p>\n  Applied <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO. \n</p>\n<p>\n  Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson &amp; Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position. \n</p>\n<p>\n  \"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director. \n</p>\n<p>\n  Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas. \n</p>\n<p>\n  Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role. \n</p>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 07:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied Therapeutics CEO Shendelman Steps Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied Therapeutics CEO Shendelman Steps Down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-20 20:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<p>\n  Applied <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO. \n</p>\n<p>\n  Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson &amp; Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position. \n</p>\n<p>\n  \"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director. \n</p>\n<p>\n  Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas. \n</p>\n<p>\n  Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role. \n</p>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 07:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492417688","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492417688","pubTimestamp":1734698100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO.Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position.\"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director.Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the c","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"应用治疗公司首席执行官申德尔曼辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLT":0.9,"LENZ":1},"content_text":"By Paul Ziobro \n\n\n  Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO. \n\n\n  Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position. \n\n\n  \"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director. \n\n\n  Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas. \n\n\n  Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role. \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 07:35 ET (12:35 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}